©2025 Stanford Medicine
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Recruiting
I'm InterestedTrial ID: NCT06850623
Purpose
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Official Title
A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Stanford Investigator(s)
Pejman Ghanouni, MD, PhD
Professor of Radiology (Body MRI) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
George A Fisher
Colleen Haas Chair in the School of Medicine, Emeritus
Eligibility
Inclusion Criteria:
* Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with inoperable LAPC or borderline resectable pancreatic cancer.
* Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment.
Exclusion Criteria:
• Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.
Intervention(s):
combination_product: Acoustic Cluster Therapy
drug: Modified FOLFIRINOX
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Britney Williams
650-736-3688
Stanford Cancer Center Palo Alto
Stanford,
California
94305
Isabel Leonio ( Study Coordinator)
Stanford Cancer Center Palo Alto
Stanford,
California
94305
Britney Williams
650-736-3688